One-component Janus dendrimers: a novel platform for efficient mRNA vaccine delivery
Tuesday, July 15, 2025
3:16 PM – 3:27 PM EDT
Introduction: Recent advances in mRNA technology and its delivery have enabled mRNA-based therapeutics into a new era of medicine (1). However, challenges persist in mRNA stability, expression duration, delivery efficiency, and target specificity. To address these challenges, we developed an one-component ionizable amphiphilic Janus dendrimer (IAJD) capable of efficiently delivering mRNA (2-3). This study demonstrates the stability and efficacy of IAJD97-based mRNA formulations as a scalable, cost-effective alternative to traditional LNPs, better suited for rapid responses to epidemiological crises.
Learning Objectives:
At the completion of this activity, participants will know
explain the advantages of the one component IAJD over traditional LNP for mRNA delivery.
Evaluate the stability, toxicity, and immune response of IAJD97-based mRNA formulations.
Assess IAJD’s potential as a scalable, cost-effective platform for rapid vaccine development.
